amyloid

According to a recent note out by Leerink, investor expectations toward one of Eli Lilly and Co (NYSE: LLY)'s drugs may need to be readjusted. During a biotech conference, panelists provided updates on Lilly's solanezumab, telling investors that the drug, while likely to be approved,...